Ajoene (natural garlic compound): A new anti-leukaemia agent for AML therapy

Leukemia Research

Volumn 28, Issue 7, 2004, Pages 667-671

  Hassan, H T ^a  

^a UNIVERSITY OF LINCOLN   (United Kingdom)

Author keywords

Ajoene; Apoptosis; CD34; Garlic; Leukaemia; Myeloid; Therapy

Indexed keywords

AJOENE; ALLICIN; CASPASE 3; CD34 ANTIGEN; CYTARABINE; FLUDARABINE; GARLIC EXTRACT; PROTEIN BCL 2; SULFIDE;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; BASAL CELL CARCINOMA; BREAST CARCINOMA; CANCER CELL CULTURE; CELL PROLIFERATION; COLORECTAL CARCINOMA; DRUG INHIBITION; ENZYME ACTIVATION; ENZYME ACTIVITY; GARLIC; HUMAN; LIVER CARCINOMA; LYMPHOMA; PRIORITY JOURNAL; PROSTATE CARCINOMA; REVIEW; SKIN TUMOR;

EID: 2442423162     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2003.10.008     Document Type: Article

References (66)

1. Agarwal K.C. Therapeutic actions of garlic constituents. Med. Res. Rev. 16:1996;111
2. Block E. The chemistry of garlic and onions. Sci. Am. 252:1985;114
3. O'Gara E.A., Hill D.J., Maslin D.M. Activities of garlic oil, garlic powder and their diallyl constituents against Helicobacter pylori. Appl. Environ. Microbiol. 66:2000;2269
4. You W.C., Zhang L., Gail M.H., Ma J.L., Chang Y.S., Blot W.J. Helicobacter pylori infection, garlic intake and pre-cancerous lesions in a Chinese population at low risk of gastric cancer. Int. J. Epidemiol. 27:1998;941
5. Takezaki T., Gao C.M., Ding J.H., Liu T.K., Li M.S., Tajima K. Comparative study of lifestyles of residents in high and low risk areas for gastric cancer in Jiangsu province, China; with special reference to allium vegetables. J. Epidemiol. 9:1999;297
6. Lamm D.L., Riggs D.R. The potential application of Allium sativum (garlic) for treatment of bladder cancer. Urol. Clin. North Am. 27:2000;157
7. Milner J.A. Mechanisms by which garlic and allyl sulfur compounds suppress carcinogen bio-activation: garlic and carcinogenesis. Adv. Exp. Med. Biol. 492:2001;69
8. Fleischauer A.T., Arab L. Garlic and cancer: a critical review of the epidemiologic literature. J. Nutr. 131(Suppl 3):2001;1032S
9. Bianchini F., Vainio H. Allium vegetables and organosulfur compounds: do they help prevent cancer? Environ. Health Perspect. 109(9):2001;893
10. Dorant E., van den Brandt P.A., Goldbohm R.A., Sturmans F. Consumption of onions and a reduced risk of stomach carcinoma. Gastroenterology. 110:1996;12
11. Ip C., Lisk D.J., Thompsom H.J. Selenium enriched garlic inhibits the early stage but not the late stage of mammary carcinogenesis. Carcinogenesis. 17:1996;1979
12. Hsing A.W., Chokkalingam A.P., Gao Y.T., Madigan M.P., Deng J., Gridley G. Allium vegetables and risk of prostate cancer: a population-based study. J. Natl. Cancer Inst. 94:2002;1648
13. Lawson LD. Garlic: a review of its medicinal effects and indicated active compounds. In: Lawson LD, Bauer R, editors. Phytomedicines of Europe: their chemistry and biological activity. Washington, DC: American Chemical Society Symposium Series 691; 1998. p. 176.
14. Ibert B., Winkler G., Knobloch K. Products of allicin transformation: ajoenes and dithins, characterisation and their determination by HPLC. Planta Med. 56:1990;202
15. Apitz-Castro R., Escalante J., Vagase R., Jain M.K. Ajoene, the antiplatelet principle of garlic, synergistically potentiates the anti-aggregatory action of prostacyclin. Thromb. Res. 42:1986;303
16. Apitz-Castro R., Badimon J.J., Badimon L. A garlic derivative, ajoene, inhibits platelet deposition on severely damaged vessel wall in an in vitro porcine experimental model. Thromb. Res. 75:1994;243
17. Apitz-Castro R., Badimon J.J., Badimon L. Effect of ajoene, the major antiplatelet compound from garlic, on platelet thrombus formation. Thromb. Res. 68:1992;145
18. Apitz-Castro R., Jain M.K., Bartolli F., Ledezma E., Ruiz M.C., Salas R. Evidence for direct coupling of primary agonist-receptor interaction to the exposure of functional IIb-IIIa complexes in human blood platelets. Results from studies with the anti-platelet compound ajoene. Biochim. Biophys. Acta. 1094:1991;269
19. Srivastava K.C., Tyagi O.C. Effects of a garlic-derived principle (ajoene) on aggregation and arachidonic acid metabolism in human blood platelets. Prostaglandins Leukot. Essent. Fatty Acids. 49:1993;587
20. Villar R., Alvarino M.T., Flores R. Inhibition by ajoene of protein tyrosine phosphatase activity in human platelets. Biochim. Biophys. Acta. 1337:1997;233
21. Gebhardt R., Beck H., Wagner K.G. Inhibition of cholesterol biosynthesis by allicin and ajoene in rat hepatocytes and HepG2 cells. Biochim. Biophys. Acta. 1213:1994;57
22. Ledezma E., Lopez J.C., Marin P., Romero H., Ferrara G., De Sousa L. Ajoene in the topical short-term treatment of tinea cruris and tinea corporis in humans. Randomized comparative study with terbinafine. Arzneimittelforschung. 49:1999;544
23. Naganawa R., Iwata N., Ishikawa K., Fukuda H., Fujino T., Suzuki A. Inhibition of microbial growth by ajoene, a sulfur-containing compound derived from garlic. Appl. Environ. Microbiol. 62:1996;4238
24. Walder R., Kalvatchev Z., Garzaro D., Barrios M., Apitz-Castro R. In vitro suppression of HIV-1 replication by ajoene [(e)-(z)-4, 5, 9-trithiadodeca-1, 6, 11-triene-9 oxide. Biomed. Pharmacother. 51:1997;397
25. Sigounas G., Hooker J.L., Li W., Anagnostou A., Steiner M. S-Allylmercaptocysteine, inhibits cell proliferation and reduces the viability of erythroleukemia, breast and prostate cancer cell lines. Nutr. Cancer. 28:1997;186
26. Siegers C.P., Steffen B., Robke A., Pentz R. The effects of garlic preparations against human tumour cell proliferation. Phytomedicine. 6:1999;7
27. Scharfenberg K., Ryll T., Wagner R., Wagner K.G. Injuries to cultivated BJA-B cells by ajoene, a garlic-derived natural compound: cell viability, glutathione metabolism and pools of acidic amino acids. J. Cell Physiol. 158:1994;55
28. Reddy B.S., Rao C.V., Rivenson A., Kelloff G. Chemo-prevention of colon carcinogenesis by organosulfur compounds. Cancer Res. 53:1993;3493
29. Pinto J.T., Qiao C., Xing J., Rivlin R.S., Protomastro M.L., Weissler M.L., et al. Effects of garlic thioallyl derivatives on growth, glutathione concentration, and polyamine formation of human prostate carcinoma cells in culture. Am. J. Clin. Nutr. 66:1997;398
30. Thatte U., Bagadey B., Dahanukar S. Modulation of programmed cell death by medicinal plants. Cell Mol. Biol. 46:2000;199
31. Nishikawa T., Yamada N., Hattori A., Fukuda H., Fujino T. Inhibition by ajoene of skin-tumour promotion in mice. Biosci. Biotechnol. Biochem. 66:2002;2221
32. Tilli C.M.L.J., Stavast-Kooy A.J.W., Vuerstaek J.D., Thissen M.R., Krekels G.A., Ramaekers F.C., et al. The garlic derived organosulfur component ajoene decreases basal cell carcinoma tumour size by inducing apoptosis. Arch. Dermatol. Res. 295:2003;117
33. Sigounas G., Hooker J.L., Li W., Anagnostou A., Steiner M. S-Allylmercaptocysteine, a stable thioallyl compound, induces apoptosis in erythroleukemia cell lines. Nutr. Cancer. 28:1997;153
34. Dirsch V.M., Gerbes A.L., Vollmar A.M. Ajoene, a compound of garlic, induces apoptosis in human promyelocytic leukaemia cells, accompanied by generation of reactive oxygen species and activation of nuclear factor kappaB. Mol. Pharmacol. 53:1998;402
35. Dirsch V.M., Antlsperger D.S., Hentze H., Vollmar A.M. Ajoene, an experimental anti-leukemic drug: mechanism of cell death. Leukemia. 16:2002;74
36. Li M., Min J.M., Cui J.R., Zhang L.H., Wang K., Valette A., et al. Z-ajoene induces apoptosis of HL-60 cells: involvement of bcl-2 cleavage. Nutr. Cancer. 42:2002;241
37. Li M., Cui J.R., Ye Y., Min J.M., Zhang L.H., Wang K. Anti-tumour activity of Z-ajoene, a natural compound purified from garlic: antimitotic and microtubule-interaction properties. Carcinogenesis. 23:2002;573
38. Ahmed N., Laverick L., Sammons J., Zhang H., Maslin D., Hassan H.T. Ajoene, a garlic-derived natural compound, enhances chemotherapy-induced apoptosis in human myeloid leukaemia CD34 positive CD7 negative resistant cells. Anticancer Res. 21:2001;3519
39. Vario G., Innes K.M., Adams J.M. Bcl-2 has a cell cycle inhibitory function separable from its enhancement of cell survival. Oncogene. 13:1996;1511
40. Yang J., Lui X., Bhalla K., Kim C.N., Ibrado A.M., Cai J., et al. Prevention of apoptosis by bcl-2: release of cytochrome c from mitochondria blocked. Science. 275:1997;1129
41. Ahmed N., Laverick L., Sammons J., Baumforth K.R.N., Hassan H.T. Effect of all-trans retinoic acid on chemotherapy induced apoptosis and down regulation of bcl-2 in human myeloid leukaemia CD34-positive cells. Leuk. Res. 23:1999;741
42. Fardel O., Payen L., Courtois A., Drenou B., Fauchet R., Rault B. Differential expression and activity of P-glycoprotein and multi-drug resistance-associated protein in CD34-positive KG1a leukemic cells. Int. J. Oncol. 12:1998;315
43. Marks D.C., Su G.M., Davey R.A., Davey M.W. Extended multi-drug resistance in haemopoeitic cells. Br. J. Haematol. 95:1996;587
44. Hassan H.T., Zander A.R. Haematopoietic cytokines in the biology and treatment of acute myeloid leukaemia. Oncol. Rep. 4:1997;1141
45. Hassan HT, Freund M. Stem cell factor protects CD34-positive human myeloid leukaemia cells from chemotherapy-induced apoptosis. In: Pieters R, editor. Drug resistance in leukemia and lymphoma. Harwood: Gordon and Breach; 1995. p. 123.
46. Hassan HT, Gutensohn K, Zander AR, Kuehnl P. CD34 positive cell sorting and enrichment: applications in blood banking and transplantation. In: Recktenwald D, Radbruch A, editors. Cell separation methods and applications. New York: Marcel Dekker; 1998. p. 283.
47. Campos L., Rouault J.P., Sabido O., Oriol P., Roubi N., Vasselon C., et al. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood. 81:1993;3091
48. Porwit-MacDonald A., Ivory K., Wilkinson S., Wheatley K., Wong L., Janossy G. Bcl-2 expression in normal human bone marrow precursors and in acute myeloid leukemia. Leukemia. 9:1995;1191
49. Lauria F., Raspadori D., Rondelli D., Ventura M.A., Fiacchini M., Visani G., et al. High bcl-2 expression in acute myeloid leukemia cells correlates with CD34 positivity and complete remission rate. Leukemia. 11:1997;2075
50. Bradbury D.A., Zhu Y.M., Russell N.R. Bcl-2 expression in acute myeloblastic leukaemia: relationship with autonomous growth and CD34 antigen expression. Leuk. Lymph. 24:1997;221
51. Karakus T., Maurer U., Weidmann E., Miething C.C., Hoelzer D., Bergmann L. High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia. Ann. Oncol. 9:1998;159
52. Dalal B.I., Wu V., Barnett M.J. Induction failure in de novo AML is associated with expression of high levels of CD34 antigen by the leukemic blasts. Leuk. Lymph. 26:1997;299
53. Campos L., Oriol P., Sabido O., Guyotat D. Spontaneous expression of P-glycoprotein and bcl-2 in acute myeloid leukaemia blast cells. Leuk. Lymph. 27:1997;119
54. Ahmed N., Sammons J., Hassan H.T. Bcl-2 protein in human myeloid leukaemia cells and its down-regulation during chemotherapy-induced apoptosis. Oncol. Rep. 6:1999;403
55. Miwa H., Nakase K., Kita K. Biological characteristics of CD7-positive acute myeloid leukaemia. Leuk. Lymph. 21:1996;239
56. Venditti A., del Poeta G., Buccisano F., Tamburini A., Cox-Froncillo M.C., Aronica G., et al. Prognostic relevance of the expression of TdT and CD7 in 335 cases of acute myeloid leukaemia. Leukemia. 12:1998;1056
57. Del Poeta G., Venditti A., Stasi R., Aronica G., Cox M.C., Buccisano F., et al. P-glycoprotein and terminal transferase expression identify prognostic subsets within cytogenetic risk classes in acute myeloid leukemia. Leuk. Res. 23:1999;451
58. Saxena A., Sheridan D.P., Card R.T., McPeek A.M., Mewdell C.C., Skinnider L.F. Biologic and clinical significance of CD7 expression in acute myeloid leukaemia. Am. J. Hematol. 58:1998;278
59. Tothova E., Elbertova A., Fricova M., Kafkova A., Hlebaskova M., Svorcova E., et al. P-glycoprotein expression in adult acute myeloid leukemia: correlation with induction treatment outcome. Neoplasma. 48:2001;393
60. Casasnovas R.O., Slimane F.K., Garand R., Faure G.C., Campos L., Deneys V., et al. Immunological classification of acute myeloblastic leukemias: relevance to patient outcome. Leukemia. 17:2003;515
61. Del Poeta G., Stasi R., Aronica G., Venditti A., Cox M.C., Bruno A., et al. Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukaemia. Blood. 87:1996;1997
62. Hassan H.T., Rees J.K.H. Relation between age and blast cell differentiation in acute myeloid leukaemia patients. Oncology. 47:1990;439
63. Venditti A., Del Poeta G., Buccisano F., Tamburini A., Cox-Froncillo M.C., Bruno A., et al. Biological features of acute myeloid leukemia in the elderly. Blood. 92(2):1998;697
64. Cascavilla N., Melillo L., D'Arena G., Greco M.M., Carella A.M., Sajeva M.R. Minimally differentiated acute myeloid leukemia (AML M0): clinico-biological findings of 29 cases. Leuk. Lymph. 37(1-2):2000;105-113
65. Huang S.Y., Tang J.L., Jou S.T., Tsay W., Hu C.H., Lin D.T. Minimally differentiated acute myeloid leukemia in Taiwan: predominantly occurs in children less than 3 years and adults between 51 and 70 years. Leukemia. 13:1999;1506
66. Stasi R., Venditti A., Del Poeta G., Aronica G., Dentamaro T., Cecconi M., et al. Intensive treatment of patients age 60 years and older with de novo acute myeloid leukemia: analysis of prognostic factors. Cancer. 77:1996;2476